February 25, 2025
Indian Biomanufacturing Alliance: Boosting National Capabilities
Indian drugmakers, biomanufacturing, trade group, collaboration, national sector growth
Hims eyes growth in its weight loss business, despite end of semaglutide shortage
semaglutide, weight loss business, United States Food and Drug Administration, Growth, Hims
Johnson & Johnson Sues Samsung Bioepis Over Alleged Stelara Biosimilar Contract Breach
Johnson & Johnson, Samsung Bioepis, Stelara, biosimilar, lawsuit, contract breach, ustekinumab, Pyzchiva
Compounders Sue FDA Over Removal of Semaglutide from Drug Shortage List
Semaglutide, FDA, drug shortage, compounders, lawsuit, Ozempic, Wegovy, Outsourcing Facilities Association
FDA Moves to Rehire Some Recently Fired Employees Amid Backlash
FDA, layoffs, rehiring, Trump administration, medical device industry, public health agencies
BioCity’s SC0062 Shows Promise in Phase 2 Trial for Diabetic Kidney Disease
SC0062, endothelin receptor type A (ETA) antagonist, diabetic kidney disease (DKD), proteinuria reduction, phase 2 trial, BioCity Biopharma
Regeneron gene therapy improves hearing in 10 children with rare form of hearing loss
Regeneron Pharmaceuticals, DB-OTO gene therapy, otoferlin (OTOF) gene, congenital hearing loss, intracochlear injection
Legal Battle Erupts as Deerfield Accuses Alcon of Obstructing Aurion Biotech’s IPO Plans
Aurion Biotech, Alcon Research, Deerfield Management , Initial Public Offering (IPO), Legal dispute, Biotech industry, Corporate governance, Shareholder rights, Delaware Court of Chancery